Blog

Epidermal growth factor receptor EGFR–targeted drugs represent a cornerstone in the treatment of advanced non–small cell lung cancer (NSCLC) harboring EGFR gene mutations. EGFR mutations are a major category of lung cancer biomarkers. NSCLC is…

In recent years, rare disease treatment has rapidly risen from a niche medical issue to one of the most active core areas of global pharmaceutical innovation. Advances in gene sequencing technology, breakthroughs in cell and…

In recent years, immune checkpoint inhibitors have revolutionized the field of anti-tumor treatment, among which PD-1 (programmed death protein 1) monoclonal antibodies have become a core therapeutic option for multiple advanced tumors due to their…

In the field of tenosynovial giant cell tumor (TGCT), a rare but persistent disease that impairs joint function, long-term systemic treatment options are limited. The emergence of Pimicotinib (ABSK021), a highly selective CSF-1R inhibitor developed…

In the treatment of leukemia, not all patients respond equally to standard therapies. Drug resistance and genetic mutations can significantly reduce the effectiveness of commonly used treatments, creating an urgent need for more advanced targeted…

Multiple myeloma is a chronic and often relapsing hematologic malignancy that requires long-term, repeated treatment. Over the past decade, therapeutic advances—particularly the introduction of monoclonal antibodies—have significantly improved patient outcomes. ✨ Among these, Daratumumab has…

Biologic therapies have fundamentally changed how chronic inflammatory diseases are treated, shifting the focus from broad immunosuppression to targeted immune modulation. From this evolving therapeutic landscape, DengYue Medicine has closely followed the emergence of next-generation…

What is Taltz ixekizumab used for? This is a common question among patients and healthcare professionals seeking clearer information about modern biologic therapies for immune-mediated inflammatory diseases. As treatment strategies continue to evolve toward targeted…

In global oncology practice, cancer anorexia–cachexia syndrome (CACS) is a common and clinically significant complication, characterized by appetite loss, involuntary weight loss, and skeletal muscle wasting. This condition not only reduces quality of life but…

Lung cancer has long been one of the leading causes of cancer incidence and mortality worldwide. With rapid advances in molecular biology, immunology, and drug development, lung cancer treatment is undergoing a profound transformation. In…

Prostate cancer remains one of the most commonly diagnosed malignancies among men worldwide, and despite significant advances in diagnosis and treatment, disease progression and therapeutic resistance continue to pose major clinical challenges. Ariane (rezvilutamide) as…

For patients diagnosed with HR-positive, HER2-negative breast cancer, treatment is often not a single drug but a carefully designed strategy. Among the most important advances in recent years is the introduction of CDK4/6 inhibitors, and…